Analystreport

Regeneron Pharmaceuticals (REGN) is now covered by Barclays PLC. They set an "overweight" rating and a $923.00 price target on the stock.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com